Nasdaq Mtcr News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq mtcr. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Mtcr Today - Breaking & Trending Today

Metacrine (NASDAQ:MTCR) Stock Price Up 1.3%

Shares of Metacrine, Inc. (NASDAQ:MTCR – Get Rating) traded up 1.3% on Thursday . The company traded as high as $0.56 and last traded at $0.56. 81,778 shares traded hands during trading, a decline of 72% from the average session volume of 288,585 shares. The stock had previously closed at $0.55. Metacrine Price Performance The […] ....

San Diego , United States , Tang Capital Management , Millennium Management , Metacrine Company Profile , Citadel Advisors , Metacrine Inc , Capital Management , Get Rating , Street Group , Metacrine Daily , Nasdaq Mtcr ,

Metacrine (MTCR) Set to Announce Earnings on Thursday

Metacrine (NASDAQ:MTCR – Get Rating) will be posting its quarterly earnings results on Thursday, April 13th. Metacrine Stock Up 1.6 % NASDAQ MTCR traded up $0.01 on Wednesday, reaching $0.57. The company had a trading volume of 32,406 shares, compared to its average volume of 348,464. The company has a quick ratio of 12.15, a […] ....

United States , San Diego , Michael York , Preston Klassen , Millennium Management , Metacrine Inc , York Mellon Corp , Metacrine Company Profile , Citadel Advisors , Get Rating , Street Corp , Street Group , New York Mellon Corp , Metacrine Daily , Nasdaq Mtcr ,

Metacrine (NASDAQ:MTCR) Rating Lowered to Hold at Zacks Investment Research

Metacrine (NASDAQ:MTCR – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Thursday, Zacks.com reports. According to Zacks, “Metacrine Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing therapies for patients with liver and gastrointestinal diseases. The company’s […] ....

United States , San Diego , Goldman Sachs Group Inc , Metacrine Company Profile Get Rating , Zacks Investment Research , Renaissance Technologies , America Corp , York Mellon Corp , Venture Management , Metacrine Inc , Get Rating , Sachs Group , New York Mellon Corp , Company Profile , Nasdaq Mtcr ,

Metacrine (NASDAQ:MTCR) Downgraded by Zacks Investment Research to "Hold"

Zacks Investment Research cut shares of Metacrine (NASDAQ:MTCR – Get Rating) from a buy rating to a hold rating in a research report report published on Thursday, Zacks.com reports. According to Zacks, “Metacrine Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing therapies for patients with liver and gastrointestinal diseases. The […] ....

United States , San Diego , Goldman Sachs Group Inc , Metacrine Company Profile Get Rating , Virtu Financial , Zacks Investment Research , Renaissance Technologies , York Mellon Corp , Venture Management , Metacrine Inc , Get Rating , New York Mellon Corp , Sachs Group , Company Profile , Nasdaq Mtcr ,

Metacrine, Inc. (NASDAQ:MTCR) Sees Large Decline in Short Interest

Metacrine, Inc. (NASDAQ:MTCR – Get Rating) was the recipient of a significant drop in short interest during the month of April. As of April 30th, there was short interest totalling 808,600 shares, a drop of 33.7% from the April 15th total of 1,220,000 shares. Based on an average trading volume of 1,730,000 shares, the short-interest […] ....

United States , York Mellon Corp , Goldman Sachs Group Inc , Zacks Investment Research , Renaissance Technologies , Metacrine Inc , America Corp , Get Rating , New York Mellon Corp , Sachs Group , Nasdaq Mtcr ,